[Pubmed] Generation of an induced pluripotent stem cell line from a malignant melanoma patient who developed the immune
Posté : 12 août 2025 12:00
Stem Cell Res. 2025 Aug 6;87:103797. doi: 10.1016/j.scr.2025.103797. Online ahead of print.
ABSTRACT
Immune checkpoint inhibitors (ICI) are a pivotal class of immuno-oncology therapeutics that have improved survival rates for patients with cancer. Their widespread usage, however, is limited due to the development of serious and potentially deadly ICI-related side effects. To develop novel diagnostic and therapeutic strategies to identify and treat patients at risk, we need a better understanding of the underlying mechanisms mediating these potentially deadly side effects. To reach this goal, we have generated and validated induced pluripotent stem cells from the peripheral blood mononuclear cells of a melanoma patient who developed ICI-related myasthenia gravis, myositis, and myocarditis overlap syndrome.
PMID:40795579 | DOI:10.1016/j.scr.2025.103797
Source: https://pubmed.ncbi.nlm.nih.gov/4079557 ... t9+e462414